Darryl P. Toth, MD, FRCPC

XLR8 Medical Research
2425 Tecumseh Road East, Suite 210
Windsor, Ontario, Canada
N8W 1E6


Specialty: Dermatology


Research Interests: Psoriasis, Psoriatic Arthritis, Eczema, Acne, Onychomycosis, Actinic Keratoses, Seborrheic Dermatitis

Dr. Darryl Toth is a board certified dermatologist who has been practicing dermatology in Windsor, Ontario since 1996. Currently, Dr. Toth is the Chief of Dermatology for two major hospitals in the Windsor area, Windsor Regional Hospital and Hotel-Dieu Grace Hospital.

In 2000, Dr. Toth began conducting clinical research trials and has conducted over 50 clinical trials in dermatology for indications such as psoriasis, psoriatic arthritis, and acne. In 13 of the phase II and III psoriasis studies that Dr. Toth has participated in, he has been in the top 5 enrollment worldwide.

Dr. Toth's experienced staff includes 2 research coordinators and a research assistant. This site has been inspected by the FDA for a pivotal phase III study and did not receive a Form 483 or any significant findings. As a result of his clinical trial experience Dr. Toth has authored many publications and has emerged as one of the top sites internationally in psoriasis clinical trials. 


Click to view Dr. Darryl Toth's Publications

Bissonnette R, Luger T, Thaçi D, Toth D, Messina I, You R, Guana A, Fox T, Papavassilis C, Gilloteau I, Mrowietz U. Secukinumab sustains good efficacy and favourable safety in moderate to severe psoriasis up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol 2017 Oct; 177(4): 1033-42. Epub 2017 Sep 4. PMID: 28580579 / doi: 10.1111/bjd.15706

Papp K, Albrecht L, Barber K, Bourcier M, Dion P-L, Freiman A, Gooderham M, Guenther L, Gulliver W, Hong C, Lynde C, Poulin Y, Siddha S, Toole J, Toth D, Vender R, Wasel N, Wiseman M. An open letter to Health Canada. J Cutan Med Surg 2017; 21(3): 195-6. doi: 10.1177/1203475417704642

Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Two Phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016 Dec 15; 375(24): 2335-48. Epub 2016 Sep 30. PMID: 27690741

Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Thaçi D, Krueger JG, Russell CB, Milmont CE, Li J, Klekotka PA, Kricorian G, Nirula A. A prospective phase 3, randomised, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016 Aug; 175(2): 273-86. Epub 2016 Jun 23. PMID: 26914406 / doi: 10.1111/bjd.14493

Sobell JM, Foley P, Toth D, Mrowietz U, Girolomoni G, Goncalves J, Day RM, Chen R, Yosipovitch G. Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis. Acta Derm Venereol 2016 May; 96(4): 514-20. PMID: 26837052 / doi: 10.2340/00015555-2360

Sobell JM, Foley P, Toth D, Mrowietz U, Girolomoni G, Goncalves J, Day RM, Chen R, Yosipovitch G. Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis. Acta Derm Venereol 2016 May; 96(4): 514-20. PMID: 26837052 / doi: 10.2340/00015555-2360

Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R; OPT Pivotal 1 and OPT Pivotal 2 investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol 2015 Oct; 173(4):949-61. PMID: 26149717 / doi: 10.1111/bjd.14018

Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015 Oct; 373(14):1318-28. PMID: 26422722 / doi: 10.1056/NEJMoa1503824

Mrowietz U, Leonardi CL, Girolomoni G, Toth D, Morita A, Balki SA, Szepietowski JC, Regnault P, Thurston H, Papavassilis C; SCULPTURE Study Group. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol 2015 Jul; 73(1):27-36.e1. Epub 2015 May 14. PMID: 25982539 / doi: 10.1016/j.jaad.2015.04.011

Stein Gold L, Kircik L, Fowler J, Jackson JM, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M, Lynde C, Sugarman J, Liu H, Jacovella J; Ivermectin Phase 3 Study Group. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol 2014 Nov; 13(11):1380-6. PMID: 25607706

Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB; PSUMMIT 2 Study Group. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicenter, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014 Jun; 73(6): 990-9. Epub 2014 Jan 30. PMID: 24482301 / doi: 10.1136/anntheumdis-2013-204655

McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK; on behalf of the PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013 Aug 31; 382(9894): 780-9. Epub 2013 Jun 12. PMID: 23769296 / doi: 10.1016/S0140-6736(13)60594-2

Brodell RT, Schlosser BJ, Rafal E, Toth D, Tyring S, Wertheimer A, Kerrouche N, Bucher D.  A fixed-dose combination of adapalene 0.1%-BPO 2.5% allows an early and sustained improvement in quality of life and patient treatment satisfaction in severe acne.  J Dermatolog Treat 2012 Feb; 23(1):26-34.  Epub 2012 Jan 4.  PMID: 22103674

Kunynetz R, Carey W, Thomas R, Toth D, Trafford T, Vender R.  Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study.  Eur J Dermatol 2011 Jan-Feb; 21(1):89-94.  PMID: 21227890

Papp KA, Poulin Y, Bissonnette R, Bourcier M, Toth D, Rosoph L, Poulin-Costello M, Setterfield M, Syrotuik J.  Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.  J Am Acad Dermatol 2012 Feb; 66(2):e33-e45.  Epub 2010 Sep 17.  PMID: 20850895

Langley RG, Papp K, Bissonnette R, Toth D, Matheson R, Hultquist M, White B.  Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies.  Int J Dermatol 2010 Jul; 49(7):818-828.  PMID: 20618506

Bissonnette R, Langley RG, Papp K, Matheson R, Toth D, Hultquist M, Geba GP, White B.  Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab. Arch Dermatol Res 2009 Jul; 301(6):429-442.  Epub 2009 May 27. PMID: 19471949

Gollnick HP, Draelos Z, Glenn MJ, Rosoph LA, Kaszuba A, Cornelison R, Gore B, Liu Y, Graeber M; Adapalene-BPO Study Group.  Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients.  Br J Dermatol 2009 Nov; 161(5):1180-1189.  Epub 2009 May 21.  PMID: 19466959

Toth DP, Papp K, Gratton D.  Long-term efficacy of up to 15 months' efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis.  Dermatol Ther 2008 Nov-Dec; 21 (Suppl 3):S6-S14.  PMID: 19076630

Menter A, Hamilton TK, Toth DP, Leung HM, Wetherill G, Hennessey B, Garovoy M, Kwon P, Pariser DM; Efalizumab Study Group.  Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, phase IIIb study.  Int J Dermatol 2007 Jun; 46(6):637-648.  PMID: 17550570

Papp KA, Toth D, Rosoph L.  Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence.  BMC Dermatol 2006 Oct; 6:9.  PMID: 17067371

Leonardi CL, Toth D, Cather JC, Langley RG, Werther W, Compton P, Kwon P, Wetherill G, Curtin F, Menter A.  A review of malignancies observed during efalizumab (Raptiva®) clinical trials for plaque psoriasis. Dermatology 2006; 213(3):204-214.  PMID: 17033169

Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM.  Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.  J Am Acad Dermatol 2006 Oct; 55(4): 598-606.  Epub 2006 Aug 10.  PMID: 17010738

Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, Papp K, Rundle AC, Toth D. Relapse, rebound, and psoriasis adverse events: an advisory group report.  J Am Acad Dermatol 2006 Apr; 54(4 Suppl 1): S171-S181.  PMID: 16488339

Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D; Efalizumab Study Group.  A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.  N Engl J Med 2003 Nov; 349(21):2004-2013.  PMID: 14627785

Gulliver WP, Bissonnette RB, … Toth DP.  Efalizumab (RaptivaTM) therapy improves patient-reported outcomes in patients with moderate to severe plaque psoriasis: results from a randomized phase III trial.  Therapy improves patient-reported outcomes in patients with moderate to severe plaque psoriasis: results from a randomized phase III trial.  Federation of Clinical Immunology Societies, submitted Jan 20, 2003.

Toth DP, Guenther LC, Shum DT.  Proliferating cell nuclear antigen (PCNA); prognostic value in the clinical recurrence of primary basal cell carcinoma.  J Dermatol Sci 1996 Jan; 11(1):36-40.  PMID: 8867765

R.G. Sibbald, S.J. Landolt, D. Toth. Skin and diabetes. Endocrinol Metab Clin North Am 1996; 25(2):463-472. PMID: 8799710

Copyright 2014 Probity Medical Research Inc. All Rights Reserved.